Please cite this article in press F. Nishvanth et al., An Overview On Emerging Of Viral Diseases In India And Future Prospectives On Their Treatment, Indo Am. J. P. Sci, 2024; 11 (09).

1. Wu KJ (15 April 2020). “There are more viruses than stars in the universe. Why do only some infect us? – More than a quadrillion quadrillion individual viruses exist on Earth, but most are not poised to hop into humans. Can we find the ones that are?”. National Geographic Society. Archived from the original on 15 April 2020. Retrieved 18 May 2020.
2. Koonin EV, Senkevich TG, Dolja VV (September 2006). “The ancient Virus World and evolution of cells”. Biology Direct. 1 (1): 29. doi:10.1186/1745-6150-1-29. PMC 1594570. PMID 16984643.
3. Zimmer C (26 February 2021). “The Secret Life of a Coronavirus – An oily, 100-nanometer-wide bubble of genes has killed more than two million people and reshaped the world. Scientists don’t quite know what to make of it”. The New York Times. Archived from the original on 28 December 2021. Retrieved 28 February 2021.
4. Lawrence CM, Menon S, Eilers BJ, Bothner B, Khayat R, Douglas T, et al. (May 2009). “Structural and functional studies of archaeal viruses”. The Journal of Biological Chemistry. 284 (19):12599603. doi:10.1074/jbc.R800078200. PMC 2675988. PMID 19158076.
5. Edwards RA, Rohwer F (June 2005). “Viral metagenomics”. Nature Reviews. Microbiology. 3 (6):50410. doi:10.1038/nrmicro1163. PMID 15886693. S2CID 8059643.Dimmock NJ, Easton AJ, Leppard K (2007). Introduction to Modern Virology (6th ed.). Blackwell Publishing. ISBN 978-1-4051-3645-7.
6. “Virus Taxonomy: 2022 Release”. talk.ictvonline.org. International Committee on Taxonomy of Viruses. Retrieved 27 April 2023.
7. Breitbart M, Rohwer F (June 2005). “Here a virus, there a virus, everywhere the same virus?”. Trends in Microbiology. 13 (6):27884. doi:10.1016/j.tim.2005.04.003. PMID 15936660
8. Caspar DLD: Design principles in virus particle construction. In Horsfall FL, Tamm I (eds): Viral and Rickettsial Infections in Man. 4th Ed. JB Lippincott, Philadelphia, 1975.
9. Fields BN (ed): Virology. 3rd Ed. Lippincott-Raven Press, 1995 .
10. Lwoff A. The concept of virus. Journal of General Microbiology. 1957;17(2):239–253. doi: 10.1099/00221287-17-2-239.
11. (http://courses.bio.indiana.edu/M430-Taylor/history.html).
12. Raoult D, Audic S, Robert C, Abergel C, Renesto P, Ogata H, La Scola B, Suzan M, Claverie JM. The 1.2-megabase genome sequence of Mimivirus. Science.2004;306(5700):1344–1350. doi: 10.1126/science.1101485.
13. Fraenkel-Conrat H, Singer B. Virus reconstitution. II. Combination of protein and nucleic acid from different strains. Biochimica et Biophysica Acta. 1957;24(3):540–548. doi: 10.1016/0006-3002(57)90244-5.
14. Goldmann DA. Transmission of viral respiratory infections in the home. The Pediatric Infectious Disease Journal. 2000;19(10 Suppl): S97–S102. doi: 10.1097/00006454-200010001-00002.
15. Hall CB, Douglas RG, Jr, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. Journal of Infectious Diseases. 1980;141(1):98–102. doi: 10.1093/infdis/141.1.98.
16. Winther B, McCue K, Ashe K, Rubino JR, Hendley JO. Environmental contamination with rhinovirus and transfer to fingers of healthy individuals by daily life activity. Journal of Medical Virology. 2007;79(10):1606–1610. doi: 10.1002/jmv.20956.
17. Dick EC, Jennings LC, Mink KA, Wartgow CD, Inhorn SL. Aerosol transmission of rhinovirus colds. Journal of Infectious Diseases. 1987;156(3):442–448. doi: 10.1093/infdis/156.3.442.
18. Laura D Kramer. Merck Manual Consumer Version. Overview of viral infections. Revised on March 2023.
19. Dikid T, Jain SK, Sharma A, Kumar A, Narain JP. Emerging & re-emerging infections in India: An overview. Indian J Med Res. 2013;138:19–31.
20. World Health Organization, South-East Asia Region, Western Pacific Region. Asia Pacific strategy for emerging diseases: 2010. New Delhi, Manila: WHO, South-East Asia Region, Western Pacific Region; 2011.
21. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen V, et al. Avian Influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004;350:1179–88.
22. Gopalakrishnan R, Sureshkumar D, Thirunarayan MA, Ramasubramanian V. Melioidosis: An emerging infection in India. J Assoc Physicians India. 2013;61:612–4.
23. Avian Influenza A H5N1 – United Kingdom of Great Britain and Northern Ireland”. www.who.int. Retrieved 2024-05-16.
24. “Influenza Type A Viruses”. U.S. Centers for Disease Control and Prevention (CDC). 2024-02-01. Retrieved 2024-05-03.
25. “Avian influenza: guidance, data and analysis”. GOV.UK. 2021-11-18. Retrieved 2024-05-09.
26. “Types of Influenza Viruses”. U.S. Centers for Disease Control and Prevention (CDC). 2023-03-30. Retrieved 2024-05-22.
27. Jump up to:a b “Influenza (Avian and other zoonotic)”. World Health Organization. 3 October 2023. Retrieved 2024-05-06.
28. Samji T (December 2009). “Influenza A: understanding the viral life cycle”. The Yale Journal of Biology and Medicine. 82 (4): 153–159. PMC 2794490. PMID 20027280.
29. Noda T (2011). “Native morphology of influenza virions”. Frontiers in Microbiology. 2: 269. doi:10.3389/fmicb.2011.00269. PMC 3249889. PMID 22291683.
30. Dadonaite B, Vijayakrishnan S, Fodor E, Bhella D, Hutchinson EC (August 2016). “Filamentous influenza viruses”. The Journal of General Virology. 97 (8): 1755–1764. doi:10.1099/jgv.0.000535. PMC 5935222. PMID 27365089.
31. Shoham D, Jahangir A, Ruenphet S, Takehara K (2012-10-04). “Persistence of avian influenza viruses in various artificially frozen environmental water types”. Influenza Research and Treatment. 2012: 912326. doi:10.1155/2012/912326. PMC 3471417. PMID 23091712.
32. ^ “Avian Influenza”. NIOSH Workplace Safety and Health Topic. National Institute for Occupational Safety and Health. 2018-10-17.
33. ^ Couch R (1996). “Chapter 58. Orthomyxoviruses Multiplication”. In Baron S (ed.). Medical Microbiology. Galveston: The University of Texas Medical Branch at Galveston. ISBN 978-0-9631172-1-2. PMID 21413353. Archived from the original on May 3, 2009.
34. Agriland, online. Scottish seals among mammals that tested positive for bird flu. Available online: https://www.agriland.co.uk/farming-news/bird-flu-found-in-seals-along-scotlands-east-coast/ [Accessed: 8 March 2023]
35. Agüero M, Monne I, Sánchez A, Zecchin B, Fusaro A, Ruano MJ, Del Valle Arrojo M, Fernández‐Antonio R, Souto AM, Tordable P, Cañás J, Bonfante F, Giussani E, Terregino C and Orejas JJ, 2023. Highly pathogenic avian influenza A(H5N1) virus infection in farmed minks, Spain, October 2022. Eurosurveill, 28(3), pii=2300001. 10.2807/1560-7917.ES.2023.28.3.2300001, 28
36. WHO Monthly Risk Assessment Summary: Influenza at the human-animal interface: https://www.who.int/teams/global-influenza-programme/avian-influenza/monthly-risk-assessment-summary
37. Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases: https://www.who.int/publications-detail-redirect/WHO-WHE-IHM-GIP-2018.2
38. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385[Erratum, N Engl J Med 2006;354:884.]
39. de Jong, M, Simmons, CP, Thanh, TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-1207
40. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A (H5N1) virus infection: guide for field operations. (Accessed December 20, 2007, at http://www.who.int/csr/resources/publications/surveillance/whocdscsredc2004.pdf.)
41. Chan, KH, Lam, SY, Puthavathana, P, et al. Comparative analytical sensitivities of six rapid influenza A antigen detection test kits for detection of influenza A subtypes H1N1, H3N2 and H5N1. J Clin Virol 2007;38:169-171.
42. Idem. Clinical management of human infection with avian influenza A (H5N1) virus. 2007. (Accessed December 20, 2007, at http://www.who.int/csr/disease/avian_influenza/guidelines/ClinicalManagement07.pdf
43. Sedyaningsih ER, Isfandari S, Setyaway V, et al. Clinical features of avian influenza A (H5N1) infection in Indonesia, July 2005–April 2007. In: Abstract book for the Options for the Control of Influenza VI Conference, Toronto, June 17–23, 2007:329.
44. Ilyushina, NA, Hoffmann, E, Solomon, R, Webster, RG, Govorkova, EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007;12:363-370
45. Morrison D, Roy S, Rayner C, et al. A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS Clin Trials (in press).
46. Le, QM, Kiso, M, Someya, K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005;437:1108-1108[Erratum, Nature 2005;438:754.]
47. Lelešius R, Karpovaite A, Mickiene R, Drevinskas T, Tiso N, RagaŽinskiene O, et al. In vitro antiviral activity of fifteen plant extracts against avian infectious bronchitis virus. BMC Vet Res. (2019) 15:1–10. 10.1186/s12917-019-1925-6
48. 54. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John’s wort Curr Drug Metab. (2008) 9:394–409. 10.2174/138920008784746391
49. 55. Chen H, Feng R, Muhammad I, Abbas G, Zhang Y, Ren Y, et al. Protective effects of hypericin against infectious bronchitis virus induced apoptosis and reactive oxygen species in chicken embryo kidney cells. Poult Sci. (2019) 98:6367–77. 10.3382/ps/pez465
50. 56. Barnes J, Arnason JT. Roufogalis BD. St John’s wort (Hypericum perforatum L): botanical, chemical, pharmacological and clinical advances. J Pharm Pharmacol. (2019) 71:1–3. 10.1111/jphp.13053
51. 57. Chen H, Muhammad I, Zhang Y, Ren Y, Zhang R, Huang X, et al. Antiviral activity against infectious bronchitis virus and bioactive components of hypericum perforatum L. Front Pharmacol. (2019) 10:1272. 10.3389/fphar.2019.01272
52. 58. Chen C, Zuckerman DM, Brantley S, Sharpe M, Childress K, Hoiczy E, et al. Sambucus nigra extracts inhibit infectious bronchitis virus at an early point during replication. BMC Vet Res. (2014) 10:1–12. 10.1186/1746-6148-10-24
53. Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection.Taniguchi K, Ando Y, Kobayashi M, Toba S, Nobori H, Sanaki T, Noshi T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A, Matsuno K, Okamatsu M, Sakoda Y, Kida H.Viruses. 2022 Jan 8;14(1):111. doi: 10.3390/v14010111.PMID: 35062315
54. Medical express. New push for mRNA bird flu vaccine development: WHO. July 29 2024.
55. Centres for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens and Pathology (DHCPP), Viral Special Pathogens Branch (VSPB). 19 October 2022. Retrieved 17 September 2023.
56. “Nipah Virus (NiV) Infection”. World Health Organization (WHO). Archived from the original on 26 September 2020. Retrieved 14 October 2020.
57. World Health Organization. 30 May 2018. Retrieved 17 September 2023.
58. Bureau TH (13 September 2023). “Nipah outbreak | Number of cases rises to 5 in Kerala; 789 contacts kept under watch”. The Hindu. ISSN 0971-751X. Retrieved 14 September 2023.
59. Millson A (14 September 2023). “What Is Nipah and Why Is the Deadly Virus Flaring Up Again”. Bloomberg.com. Retrieved 14 September 2023.
60. Nipah virus: Kerala state issues alert after 14-year-old dies”. BBC News. 21 July 2024. Retrieved 21 July 2024.
61. “Nipah death again in Kerala, 14-year-old boy under treatment dies at Kozhikode MCH”. The Hindu. 21 July 2024. Retrieved 22 July 2024.
62. Sharma V, Kaushik S, Kumar R, Yadav JP, Kaushik S (January 2019). “Emerging trends of Nipah virus: A review”. Reviews in Medical Virology. 29 (1): e2010. doi:10.1002/rmv.2010. PMC 7169151. PMID 30251294.
63. Sukhpreet kaur et.al. Ayurvedic management of nipah virus (niv) infection. World Journal of Pharmaceutical and life sciences. 2019, Vol. 5, Issue 11, 94-95.
64. K. Samraj et.al. Metal – based Nanoparticle Siddha Formulations for the Management of Emerging Infectious Diseases (EIDs). Journal of research in Siddha medicine. 2020; 3(1): 28-33.
65. Mori T, O’Keefe BR, Sowder RC 2nd, et al.: Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2005; 280(10): 9345–53. 10.1074/jbc.M411122200.
66. Lo MK, Amblard F, Flint M, et al.: Potent in vitro activity of β-D-4′-chloromethyl-2′-deoxy-2′-fluorocytidine against Nipah virus. Antiviral Res. 2020; 175: 104712. 10.1016/j.antiviral.2020.104712.
67. Lalezari JP, Henry K, O’Hearn M, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003; 348(22): 2175–85. 10.1056/NEJMoa035026
68. Corona viridae Study Group of the International Committee on Taxonomy of Viruses (April 2020). “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2”. Nature Microbiology. 5 (4): 536–544. doi:10.1038/s41564-020-0695-z. PMC 7095448. PMID 32123347.
69. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006;66:193-292. doi:10.1016/S0065-3527(06)66005-3.
70. COVID-19 epidemiological update – 15 March 2024
71. Steenhuysen J, Kelland K (24 January 2020). “With Wuhan virus genetic code in hand, scientists begin work on a vaccine”. Reuters. Archived from the original on 25 January 2020. Retrieved 25 January 2020.
72. “Treatments and vaccines for COVID-19: authorised medicines”. European Medicines Agency. 11 January 2021. Archived from the original on 19 February 2021. Retrieved 20 February 2021.
73. “COVID-19 Frequently Asked Questions: Drugs (Medicines)”. U.S. Food and Drug Administration. 19 February 2021. Archived from the original on 19 February 2021. Retrieved 20 February 2021.
74. Viswanatha GL, Anjana Male CK, Shylaja H (2022). “Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies”. Clinical and Experimental Rheumatology. 40 (3): 634–646. doi:10.55563/clinexprheumatol/4dg0or. PMID 34251307. S2CID 247725977.
75. Abdool Karim SS, Devnarain N (August 2022). “Time to Stop Using Ineffective Covid-19 Drugs”. The New England Journal of Medicine. 387 (7): 654–655. doi:10.1056/NEJMe2209017. PMID 36070715. S2CID 251658284.
76. M. Kannan et.al. Safety and efficacy of a Siddha Medicine fixed regimen for the treatment of asymptomatic and mild COVID-19 patients. Journal of Ayurveda and integrative medicine. 2022 Jul-Sep; 13(3): 100589.Published online 2022 May 23. doi: 10.1016/j.jaim.2022.100589
77. Nithiya sivan et.al. Ayurvedic treatment of COVID-19/SARS-CoV-2: A case report. Journal of Ayurveda and integrative medicine. 2022 Jan-Mar; 13(1): 100329. Published online 2020 Jun 19. doi: 10.1016/j.jaim.2020.06.001
78. FDA Authorizes First Oral Antiviral for Treatment of COVID-19. U.S. Food and Drug Administration (FDA). 22 December 2021. Retrieved 22 December 2021. This article incorporates text from this source, which is in the public domain.
79. ^ Whipple T (23 October 2021). “Moonshot is the spanner in the Covid-19 works the country needs”. The Times. Retrieved 5 November 2021.
80. “Guidelines on the Treatment and Management of Patients with COVID-19”. Infectious Diseases Society of America (IDSA).
81. “Coronavirus Disease 2019 (COVID-19) Treatment Guidelines”. National Institutes of Health.
82. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. (20 May 2021). “Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review”. The Cochrane Database of Systematic Reviews. 2021 (5): PMID 34013969
83. Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, Schneider A, et al. (March 2016). “Zika Virus: Medical Countermeasure Development Challenges”. PLOS Neglected Tropical Diseases. 10 (3): e0004530. doi:10.1371/journal.pntd.0004530. PMC 4774925. PMID 26934531
84. “ViralZone: Zika virus (strain Mr 766)”. viralzone.expasy.org. SIB Swiss Institute of Bioinformatics. Retrieved 24 August 2016.
85. Pierson TC, Diamond MS (April 2012). “Degrees of maturity: the complex structure and biology of flaviviruses”. Current Opinion in Virology. 2 (2): 168–175. doi:10.1016/j.coviro.2012.02.011. PMC 3715965. PMID 22445964
86. de Araújo TVB, Ximenes RA de A, Miranda-Filho D de B, et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: Final report of a case-control study. Lancet Infect Dis. 3099(17)30727-2
87. Sumit Bhardwaj et.al. Zika virus: Current concerns in India. Indian J Med Res. 2017 Nov; 146(5): 572–575. doi: 10.4103/ijmr.IJMR_1160_17
88. The Indian Express (Journalism of Courage). Saturday Aug 3, 2024.
89. Prajakta Darekar et.al. Ayurvedic remedies of zika virus (zikv). World Journal of Pharmacy and Pharmaceutical sciences. Volume 11, Issue 4, 2275-2286. DOI: 10.20959/wjpps20224-21831.
90. Sagonowsky E (21 June 2016). “Inovio set for first Zika vaccine human trial”. fiercepharma.com. Retrieved 1 July 2016.
91. Fernandez E, Diamond MS (April 2017). “Vaccination strategies against Zika virus”. Current Opinion in Virology. 23: 59–67. doi:10.1016/j.coviro.2017.03.006. PMC 5576498. PMID 28432975.
92. Xu M., Lee E.M., Wen Z., Cheng Y., Huang W.-K., Qian X., Tcw J., Kouznetsova J., Ogden S.C., Hammack C., et al. Identification of Small-Molecule Inhibitors of Zika Virus Infection and Induced Neural Cell Death via a Drug Repurposing Screen. Nat. Publ. Gr. 2016;22:1–9. doi: 10.1038/nm.4184.
93. Kato F., Ishida Y., Oishi S., Fujii N., Watanabe S., Vasudevan S.G., Tajima S., Takasaki T., Suzuki Y., Ichiyama K., et al. Novel Antiviral Activity of Bromocriptine against Dengue Virus Replication. Antiviral Res. 2016;131:141–147. doi: 10.1016/j.antiviral.2016.04.014.
94. Barbosa-Lima G., Moraes A.M., da Araújo A.S., da Silva E.T., de Freitas C.S., Vieira Y.R., Marttorelli A., Neto J.C., Bozza P.T., de Souza M.V.N., Souza T.M.L. 2,8-Bis(trifluoromethyl)quinoline Analogs Show Improved Anti-Zika Virus Activity, Compared to Mefloquine. Eur. J. Med. Chem. 2017;127:334–340. doi: 10.1016/j.ejmech.2016.12.058.
95. “Mpox (monkeypox) outbreak 2022”. www.who.int. Archived from the original on 2023-01-07. Retrieved 2023-01-07.
96. Shaju P. 35-yr-old from Kerala is India’s first monkeypox case; centre sends team. 2022. [20 Aug 2022]. https://indianexpress.com/article/india/kerala/monkeypox-confirmed-in-kerala-man-who-returned-from-uae-8029718/ Available from. Accessed. [Google Scholar]
97. 20. The New Indian Express. Kerala reports second monkeypox case, patient a Dubai-returned Kannur native. 2022. [27 Aug 2022]. https://www.newindianexpress.com/states/kerala/2022/jul/18/kerala-reports-second-monkeypox-case-patient-a-dubai-returned-kannur-native-2477891.html Available from. Accessed. [Google Scholar]
98. 21. Shaju P. Kerala reports third case of monkeypox in India. 2022. [27 Aug 2022]. https://indianexpress.com/article/cities/thiruvananthapuram/kerala-reports-third-case-of-monkeypox-in-india-8045413/ Available from. Accessed. [Google Scholar]
99. 22. Durgesh JN. India’s 4th monkeypox case in Delhi, patient has no foreign travel history. 2022. [27 Aug 2022]. https://timesofindia.indiatimes.com/india/indias-4th-monkeypox-case-in-delhi-patient-has-no-foreign-travel-history/articleshow/93096145.cms Available from. Accessed. [Google Scholar]
100. 23. The Indian Express. Youth who died in Kerala’s thrissur succumbed to monkeypox, says health dept after NIV confirms. 2022. [27 Aug 2022].
101. https://indianexpress.com/article/cities/thiruvananthapuram/kerala-thrissur-monkeypox-death-8063699/ Available from. Accessed.
102. Lokesh Goyal et.al. Prevention and Treatment of Monkeypox: A Step-by-Step Guide for Healthcare Professionals and General Population. Cureus. 2022 Aug; 14(8): e28230. Published online 2022 Aug 21. doi: 10.7759/cureus.28230
103. Adler, H. et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect. Dis. 22, 1153–1162 (2022).
104. Hatch, G. J. et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. J. Virol. 87, 7805–7815 (2013).
105. Saijo, M. et al. LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox. J. Virol. 80, 5179–5188 (2006).
106. Sang Y., Zhang Z., Liu F., Lu H., Yu C., Sun H., Long J., Cao Y., Mai J., Miao Y., et al. Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus. Signal Transduct. Target. Ther. 2023; 8:1–11. doi: 10.1038/s41392-023-01432-5.
107. Bhatt, P. N.; Rodrigues, F. M. (December 1967). “Chandipura: A new Arbovirus Isolated in India from Patients with Febrile Illness”. Indian Journal of Medical Research. 55 (12): 1295–1305. PMID 4970067.
108. Basak, S.; Mondal, A.; Polley, S.; Mukhopadhyay, S.; Chattopadhyay, D. (October 2007). “Reviewing Chandipura: A Vesiculovirus in Human Epidemics”. Bioscience Reports. 27 (4–5): 275–298. doi:10.1007/s10540-007-9054-z. PMC 7087735. PMID 17610154.
109. “Chandipura virus outbreak reported in Gujarat. What we know”. Hindustan Times. 2024-07-15. Archived from the original on 2024-07-15. Retrieved 2024-07-16.
110. “Four children die in Gujarat from suspected Chandipura virus infection”. Gujarat Samachar. Archived from the original on 2024-07-14. Retrieved 2024-07-14.
111. “Chandipura virus killed three, infected 11 in Maharashtra last year”. The Times of India. 2012-06-11. ISSN 0971-8257. Archived from the original on 2024-07-14. Retrieved 2024-07-14.
112. DNA Correspondent (2010-08-05). “Chandipura Virus Kills 17 in Gujarat”. DNA—Daily News & Analysis. Gandhinagar. Archived from the original on 2012-02-24. Retrieved 2012-02-24.
113. “5-year-old girl dies of Chandipura virus in Gujarat”. 17 July 2019. Archived from the original on 26 July 2019. Retrieved 26 July 2019.
114. “Chandipura Virus claims twenty lives in Gujarat: Symptoms, precautions, treatments, how it spreads and all you need to know”. The Economic Times. 2024-07-16. ISSN 0013-0389. Archived from the original on 2024-07-16. Retrieved 2024-07-16.
115. “’12 suspected cases of Chandipura viral encephalitis reported in Gujarat'”. The Times of India. 2024-07-16. ISSN 0971-8257. Archived from the original on 2024-07-16. Retrieved 2024-07-16.
116. Mohammed, Manal (2024-07-29). “India is suffering its largest Chandipura virus outbreak in 20 years –what you need to know”. The Conversation. Archived from the original on 2024-07-30. Retrieved 2024-07-30.
117. Venkateswarlu CH, Arankalle VA. Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine. 2009;27:2845–50.
118. Jadi RS, Sudeep AB, Barde PV, Arankalle VA, Mishra AC. Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus) Vaccine. 2011;29:4613–7.
119. Kumar S, Arankalle VA. Intracranial administration of P gene siRNA protects mice from lethal Chandipura virus encephalitis. PLoS One. 2010;5:e8615.